期刊文献+

台勾霉素生产菌指孢囊菌NRRL 18085遗传操作体系的建立 被引量:6

Genetic manipulation system for tiacumicin producer Dactylosporangium aurantiacum NRRL 18085
原文传递
导出
摘要 【目的】建立新型大环内酯类抗生素台勾霉素的生产菌指孢囊菌Dactylosporangium aurantiacum NRRL18085的遗传操作体系,实现台勾霉素相关生物合成基因的敲除突变。【方法】以整合型质粒pSET152为载体,建立了外源DNA通过接合转移进入指孢囊菌NRRL18085的操作方法和培养条件,利用PCR-targeting系统在体外构建了一个台勾霉素卤化酶基因敲除的cosmid质粒,通过接合转移转入到指孢囊菌NRRL18085野生菌中。【结果】获得了台勾霉素卤化酶基因敲除的指孢囊菌NRRL18085的双交换突变株,该突变株失去了产生台勾霉素的能力。【结论】成功建立和优化了指孢囊菌NRRL18085菌株的遗传操作体系,使得在体内分析和鉴定台勾霉素生物合成基因的功能成为可能,同时也为建立其他类似放线菌的遗传操作体系提供了参考。 [Objective] To optimize the production of tiacumicin B in Dactylosporangium aurantiacum NRRL 18085,we developed a genetic manipulation system for disrupting genes involved in tiacumicin biosynthesis.[Methods ] We developed a method of conjugation to transfer exotic DNA pSET152 into D.aurantiacum NRRL 18085.Using the PCRtargeting system,we disrupted a putative tiacumicin halogenase gene in vitro by"in-frame deletion"in E.coli,and then the resulting cosmid was transferred into D.aurantiacum NRRL 18085 by conjugation.[Results]The putative tiacumicin halogenase gene in D.aurantiacum NRRL 18085 was disrupted by in-frame deletion from a double-crossover recombination event.The resulting mutant strain lost the ability to produce tiacumicin B.[Conclusion]We developed a genetic manipulation system for D.aurantiacum NRRL 18085,enabling the functional characterization of tiacumicin biosynthetic genes in vivo,and we offered a positive example for other Actinobacteria lacking an appropriate genetic manipulation system.
出处 《微生物学报》 CAS CSCD 北大核心 2010年第8期1014-1022,共9页 Acta Microbiologica Sinica
基金 中国科学院知识创新工程重要方向项目(KZCX2-YW-216) 国家自然科学基金青年科学基金(30900035) 中国博士后科学基金(20090460836) 中国科学院百人计划项目(08SL111002)~~
关键词 指孢囊菌 遗传体系 台勾霉素 生物合成 卤化酶 Dactylosporangium genetic manipulation system tiacumicin biosynthesis halogenase
  • 相关文献

参考文献23

  • 1Ackermann G, Loftier B, Adler D, Rodloff AC. In vitro activity of OPT-80 against Clostridium difficile. Antimicrobial Agents and Chemotherapy, 2004, 48 (6): 2280-2282.
  • 2Karlowsky JA, Laing NM, Zhanel GG. In vitro activity of OPT-80 tested against clinical isolates of toxin- producing Clostridium difficile. Antimicrobial Agents and Chemotherapy, 2008, 52( 11 ) : 4163-4165.
  • 3Kurabachew M, Lu SH, Krastel P, Schmitt EK, Suresh BL, Goh A, Knox JE, Ma NL, Jiricek J, Beer D, Cynamon M, Petersen F, Dartois V, Keller T, Dick T, Sambandamurthy VK. Lipiarmycin targets RNA polymerase and has good activity against muhidrugresistant strains of Mycobacterium tuberculosis. Journal of Antimicrobial Chemotherapy, 2005, 62 (4) : 713-719.
  • 4Hochlowski JE, Swanson S J, Ranfranz LM, Whittern DN, Buko AM, McAlpine JB. Tiacumicins, a novel complex of 18-membered macrolides. II. Isolation and structure determination. Journal of Antibiotics, 1987, 40 (5) : 575-588.
  • 5Coronelli C, White RJ, Lancini GC, Parenti F. Lipiarmycin, a new antibiotic from Actinoplanes. II. Isolation, chemical, biological and biochemical characterization. Journal of Antibiotics, 1975, 28 (4) : 253 -259.
  • 6Shue YK, Hwang CK, Chiu YH, Romero A, Babakhani F, Sears PS, Okumu F. 18-Membered macrocycles and analogs thereof. USA: US 20080269145A1, Oct. 30, 2008.
  • 7Louie T, Miller M, Donskey C, Mullane K, Goldstein EJ. Clinical outcomes, safety, and pharmacokinetics of OPT-80 in a phase 2 trial with patients with Clostridium difficile infection. Antimicrobial Agents and Chemotherapy, 2009, 53 ( 1 ) : 223-228.
  • 8Shue YK, Sears PS, Shangle S, Walsh RB, Lee C, Gorbach SL, Okumu F, Preston RA. Safety, tolerance, and pharmacokinetic studies of OPT-80 in healthy volunteers following single and multiple oral doses. Antimicrobial Agents and Chemotherapy, 2008, 52 (4): 1391-1395.
  • 9Wu MC, Huang CC, Lu YC, Fan WJ. Derivatives of tiacumicin B as anti-cancer agents. USA: US 2009/ 0110718 A1, Apr. 30, 2009.
  • 10Gerber M, Aekermann G. OPT-80, a macrocyclic antimicrobial agent for the treatment of Clostridium difficile infections: a review. Expert Opinion on lnvestigational Drugs, 2008, 17(4) : 547-553.

二级参考文献31

  • 1郑榕,刘勇,赵宁,黄捷,程元荣,杜建国,季红兵,黄武军,聂中越.棘孢小单孢菌耐受无机磷突变株129-P1产生的新的氨基糖苷抗生素复合物GP[J].中国抗生素杂志,1994,19(6):415-420. 被引量:3
  • 2郑维,权春善,朴永哲,范圣第.一种快速提取细菌总DNA的方法研究[J].中国生物工程杂志,2006,26(4):75-80. 被引量:35
  • 3Hopwood D A. Genetic contributions to understanding polyketide synthases [J]. Chem Rev, 1997,97 (7): 2465.
  • 4Bailey J E, Birnbaum S, Galazzo J L, et al. Strategies and challenges in metabolic engineering [J]. Ann NY Acad Sci, 1990,589: 1.
  • 5Malpartida F, Hopwood D A. Molecular cloning of the whole biosynthetic pathway of a Streptom,yces antibiotic and its expression in a heterologous host [J]. Nature,1984,309(5967):462.
  • 6Malpartida F, Hallam S E, Kieser H M, et al. Homology between Streptomyces genes coding for synthesis of different polyketides used to clone antibiotic biosynthetic genes [J]. Nature,1987,325(6107):818.
  • 7Cortes J, Haydock S F, Roberts G A, et al. An unusually large multifunctional polypeptide in the erythromycin-producing polyketide synthase of Saccharopolyspora erythraea [J]. Nature,1990,348(6297): 176.
  • 8Donadio S, Stayer M J, McAlpine J B, et al. Modular organization of genes required for complex polyketide biosynthesis [J]. Science, 1991,252 (5006): 675.
  • 9I Chater K F. The improving prospects for yield increase by genetic engineering in antibiotic-producing Streptomycetes [J]. Biotechnology (N Y), 1990,8(2): 115.
  • 10Kim C G, Yu T W, Fryhle C B, et al. 3-Amino-5-hydroxybenzoic acid synthase, the terminal enzyme in the formation of the precursor of mC7N units in rifamycin and related antibiotics [J]. J Biol Chem, 1998,273(11): 6030.

共引文献106

同被引文献68

  • 1白林泉,邓子新.微生物次级代谢产物生物合成基因簇与药物创新[J].中国抗生素杂志,2006,31(2):80-86. 被引量:35
  • 2姜淑梅,张龙,戴世鲲,李翔.一种简单、有效的适于PCR操作的放线菌DNA提取方法[J].生物技术,2007,17(1):39-41. 被引量:58
  • 3王世媛.非核糖体肽合成酶(NRPSs)作用机理与应用的研究进展[J].微生物学报,2007,47(4):734-737. 被引量:22
  • 4萨姆布鲁克,拉塞尔.分子克隆实验指南[M].第三版.黄培堂译.北京:科学出版社,2002.
  • 5Tamura T, Liu ZH, Zhang YM, Hatano K. Actinoalloteichus cyanogriseus gen. nov. , sp nov. International Journal of Systematic and EvolutionarY Microbiology, 2000, 50 ( 4 ) : 1435-1440.
  • 6Singla AK, Mayilraj S, Kudo T, Krishnamurthi S, Prasad GS, Vohra RM. Actinoalloteichus spitiensi.s sp. nov. , a novel actinobacterium isolated from a cold desert of the Indian Himalayas. International Journal of Systematic and Evolutionary Microbiology, 2005, 55 (6) : 2561-2564.
  • 7Zhang HT, Zheng W, Huang JY, Luo HL, Jin Y, Zhang W, Liu ZH, Huang Y. Actinoalloteichus hymeniacidonis sp. nov. , an actinomycete isolated from the marine sponge Hymeniacidon perleve, lnternation.al Journal of Systematic and Evolutionary Microbiology, 2006, 56(10): 2309-2312.
  • 8Niu GQ, Liu G, Tian YQ,Tan HR. SanJ, an ATPdependent picolinate-CoA ligase, catalyzes the conversion of picolinate to picolinate-CoA during Nikkomycin biosynthesis in Streptomyces ansochromogenes. Metabolic Engineering, 2006, 8 ( 3 ) : 183195.
  • 9Funk A, Divekar PV. Caerulomycin, a new antibiotic from Streptomyces caeruleus Baldacci: I. Production,isolattion, assay, and biological properties. Canadian Journal of Microbiology, 1959, 5(4) : 317-321.
  • 10Divekar PV, Read G, Vining LC. Caerulomycin, a new antibiotic from Streptomyces caeruleus Baldacci. Ⅱ. Structure. Canadian Journal of Chemistry, 1967, 45 (11) : 1215-1223.

引证文献6

二级引证文献20

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部